Sanofi to develop mRNA vaccines using ex-Shire platform

By Flora Southey contact

- Last updated on GMT

Sanofi Pasteur has teamed with Translate Bio to develop mRNA vaccines for infectious diseases, using a platform developed by subsidiaries of Shire plc.

Clinical-stage mRNA therapeutics firm Translate Bio has announced a three-year collaboration with Sanofi Pasteur – the vaccine unit of Sanofi – to develop up to five undisclosed infectious disease pathogens.

Messenger RNA (mRNA) medicine works by instructing ribosomes inside cells to produce a desired therapeutic protein when injected into a platform. mRNA vaccines are designed to deliver the nucleotide sequence, encoding any protein associated with prevention or treatment of a pathogen.

According to the agreement terms, Sanofi Pasteur will fund all research and development activities – conducted jointly with Translate Bio – and pay the biotech an upfront fee of $45m (€38m) and up to $805m in tiered royalty payments.

In return, Sanofi Pasteur will receive exclusive worldwide commercialisation rights for the developed vaccines.

The firms will develop the vaccines using the MRT platform, which Translate Bio – formerly RaNA Therapeutics – acquired from Shire plc in January last year​.

“We believe mRNA technology has significant potential for rapid and versatile manufacturing, reduced industrialisation costs for multiple vaccines, and the improved breadth of immune response for infectious disease vaccines,” ​said Sanofi Pasteur’s John Shiver in a statement​.

Related topics: Delivery technologies, Drug Delivery

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us


View more